Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Wolfgang Janni, MD, PhD, Ulm University, Ulm, Germany, discusses the upcoming advances in triple-negative breast cancer (TNBC) including immunotherapy for triple-negative breast cancer as well as new targeted agents for HER2-positive breast cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
We use necessary cookies to make this site work. Analytics, preference, and marketing cookies are used only if you choose to allow them. You can change your choice at any time. For more information view our Cookie Policy.